William Blair research analyst Matt Phipps was quoted in Barron’s following the announcement of a new Medicare drug pricing structure by the Biden administration.
Equity Research
Matt Phipps Reacts to Medicare Drug Pricing Announcement in Barron’s
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
-
William Blair Initiates Coverage of Two Companies Developing Retinal Disease Therapies
William Blair initiated research coverage of Kalaris Therapeutics, Inc. (KLRS $7.08) and Ocular Therapeutix, Inc. (OCUL $6.36), both biotechnology companies developing therapies for the treatment of retinal vascular diseases.
-